Non-Surgical Management of Knee Osteoarthritis: Are Complementary Oral Medications Effective?

Abstract

Osteoarthritis (OA) is a progressive disease of the synovial joints that causes pain, functional impairment, disability, and progressive degeneration of the joint. Regarding its treatments, especially in early stages, there are different interventions to avoid its development and progression and also to achieve an adequate management of symptoms, and there are unconventional oral medical treatments with controversial evidence. The objective of the present paper is to provide an update, to specialists in Orthopedics and Traumatology, regarding the current evidence on complementary oral therapies in the treatment of knee osteoarthritis. References are made to the most widely used and studied complementary pharmacological methods, mentioning the method of action and the consequences studied on knee osteoarthritis. The article ends with a table of recommendations based on current evidence.

Keywords

osteoarthritis - pain - knee - chondroitin - diacerein - hyaluronic acid

Publikationsverlauf

Eingereicht: 30. August 2020

Angenommen: 24. September 2021

Artikel online veröffentlicht:
22. Dezember 2021

• Referencias

• 1 Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011; 377 (9783): 2115-2126 DOI: 10.1016/S0140 -6736(11)60243-2.
• 2 Vos T, Flaxman AD, Naghavi M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2163-2196 DOI: 10.1016/s0140 -6736(12)61729-2.
• 3 Bruyère O, Cooper C, Pelletier JP. et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014; 44 (03) 253-263 https://doi.org/10.1016/j . semarthrit.2014.05.014
• 4 Black C, Clar C, Henderson R. et al. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess 2009; 13 (52) 1-148 DOI: 10.3310/hta13520.
• 5 McCarty MF. The neglect of glucosamine as a treatment for osteoarthritis–a personal perspective. Med Hypotheses 1994; 42 (05) 323-327 DOI: 10.1016/0306-9877(94)90007-8.
• 6 Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998; 6 (06) 427-434 DOI: 10.1053/joca.1998.0146.
• 7 Reginster JY, Deroisy R, Rovati LC. et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357 (9252): 251-256 DOI: 10.1016/S0140-6736(00)03610-2.
• 8 Henrotin Y, Mathy M, Sanchez C, Lambert C. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Therapeutic Advances in Musculoskeletal Disease 2010; 2 (06) 335-348 DOI: 10.1177/1759720X10383076.
• 9 Mathieu P. [A new mechanism of action of chondroitin sulfates ACS4-ACS6 in osteoarthritic cartilage]. Presse Med 2002; 31 (29) 1383-1385 https://www.ncbi.nlm.nih.gov/pubmed/12375394
• 10 Simental-Mendía M, Sánchez-García A, Vilchez-Cavazos F, Acosta-Olivo CA, Peña-Martínez VM, Simental-Mendía LE. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol Int 2018; 38 (08) 1413-1428 DOI: 10.1007/s00296-018-4077-2.
• 11 Towheed TE, Maxwell L, Anastassiades TP. et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; (02) CD002946 DOI: 10.1002/14651858.CD002946.pub2.
• 12 Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken) 2014; 66 (12) 1844-1855 DOI: 10.1002/acr.22376. https://doi.org/10.1002/acr.22376
• 13 McAlindon TE, LaValley MP, Gulín JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283 (11) 1469-1475 DOI: 10.1001/jama.283.11.1469.
• 14 Reichenbach S, Sterchi R, Scherer M. et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146 (08) 580-590 DOI: 10.7326/0003-4819-146-8-200704170-00009.
• 15 Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev 2015; 1: CD005614 DOI: 10.1002/14651858.cd005614.pub2.
• 16 Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ?. Arthritis Rheum 2007; 56 (07) 2267-2277 DOI: 10.1002/art.22728.
• 17 Cameron M, Gagnier JJ, Little CV, Parsons TJ, Blümle A, Chrubasik S. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part I: Osteoarthritis. Phytother Res 2009; 23 (11) 1497-1515 [PubMed: 19856319]
• 18 Henrotin YE, Labasse AH, Jaspar JM. et al. Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheumatol 1998; 17 (01) 31-39 DOI: 10.1007/bf01450955.
• 19 Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev 2014; (05) CD002947 DOI: 10.1002/14651858.cd002947.pub2.
• 20 Christensen R, Bartels EM, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008; 16 (04) 399-408 DOI: 10.1016/j.joca.2007.10.003.
• 21 Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis 2010; 2 (02) 95-104 DOI: 10.1177/1759720 × 09359104.
• 22 Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage 2000; 8 (03) 186-196 DOI: 10.1053/joca.1999.0289.
• 23 Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol 1998; 25 (04) 753-762 https://www.ncbi.nlm.nih.gov/pubmed/9558181
• 24 Pelletier JP, Mineau F, Ranger P, Tardif G, Martel-Pelletier J. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthritis Cartilage 1996; 4 (01) 77-84 DOI: 10.1016/S1063-4584(96)80009-4.
• 25 Yaron M, Shirazi I, Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage 1999; 7 (03) 272-280 DOI: 10.1053/joca.1998.0201.
• 26 Brandt KD, Smith G, Kang SY, Myers S, O'Connor B, Albrecht M. Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cartilage 1997; 5 (06) 438-449 DOI: 10.1016/s1063-4584(97)80048-9.
• 27 Kitadai HK, Takahashi HK, Straus AH. et al. Effect of oral diacerein (DAR) in an experimental hip chondrolysis model. J Orthop Res 2006; 24 (06) 1240-1248 DOI: 10.1002/jor.20180.
• 28 Ghosh P, Xu A, Hwa SY, Burkhardt D, Little C. Evaluation des effets de la diacerhéine dans un modèle ovin d'arthrose [Evaluation of the effects of diacerhein in an ovine model of osteoarthritis]. Rev Prat 1998; 48 (17) S24-S30 French. https://doi.org/
• 29 Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2014; 2 (02) CD005117 DOI: 10.1002/14651858.CD005117.pub3.
• 30 Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med 2006; 166 (17) 1899-1906 DOI: 10.1001/archinte.166.17.1899.
• 31 Bruyère O, Cooper C, Arden N. et al. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs Aging 2015; 32 (03) 179-187
• 32 European Medicines Agency. Assessment report for diacerein containing medicinal products. EMA. 2014 Aug 28. https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-prac-assessment-report_en.pdf
• 33 Altman RD, Manjoo A, Fierlinger A, Niazi F, Nicholls M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord 2015; 16: 321 DOI: 10.1186/s12891-015-0775-z.
• 34 Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop 2014; 5 (03) 351-361 DOI: 10.5312/wjo.v5.i3.351.
• 35 Stern R, Jedrzejas MJ. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 2006; 106 (03) 818-839 DOI: 10.1021/cr050247k.
• 36 Oe M, Tashiro T, Yoshida H. et al. Oral hyaluronan relieves knee pain: a review. Nutr J 2016; 15: 11 DOI: 10.1186/s12937-016-0128-2.
• 37 Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 2003; 5 (02) 54-67 DOI: 10.1186/ar623.
• 38 Balazs EA. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int 2004; 12: 278-289 https://www.researchgate.net/publication/8260767_Viscosupplementation_for_treatment_of_osteoarthritis_From_initial_discovery_to_current_status_and_results
• 39 Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006; 19 (02) CD005321 DOI: 10.1002/14651858.CD005321.pub2.
• 40 Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis–meta-analysis. Osteoarthritis Cartilage 2011; 19 (06) 611-619 DOI: 10.1016/j.joca.2010.09.014.
• 41 Fakhari A. Biomedical application of hyaluronic acid nanoparticles. PhD thesis. 2012 Jan 19. https://kuscholarworks.ku.edu/bitstream/handle/1808/9825/Fakhari_ku_0099D_11965_DATA_1.pdf;sequence=1
• 42 Panuccio E, Memeo A, Richetta S. [Evaluation of the combined treatment of oral viscosupplementation with hyaluronic acid intra-articular injection on symptomatic knee osteoarthritis]. Clin Ter 2015; 166 (05) e321-e326 DOI: 10.7417/T.2015.1886.
• 43 Sawitzke AD, Shi H, Finco MF. et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010; 69 (08) 1459-1464 DOI: 10.1136/ard.2009.
• 44 Oesser S, Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res 2003; 311 (03) 393-399 DOI: 10.1007/s00441-003-0702-8.
• 45 Benito-Ruiz P, Camacho-Zambrano MM, Carrillo-Arcentales JN. et al. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. Int J Food Sci Nutr 2009; 60 (Suppl. 02) 99-113 DOI: 10.1080/09637480802498820.
• 46 Bruyère O, Zegels B, Leonori L. et al. Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study. Complement Ther Med 2012; 20 (03) 124-130 DOI: 10.1016/j.ctim.2011.12.007.